Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Andrew Frye Biography and Net Worth

SVP of Baxter International

Andrew Frye is senior vice president and president, APAC.

Frye joined Baxter in 2017 from DKSH Holdings Ltd., where he served as Global Head of Healthcare from 2015 to 2017. In that role, he oversaw a portfolio of pharmaceuticals, over-the-counter and device products across 13 countries. Previously, he served as vice president of Business Development from 2011 to 2014 for DKSH Healthcare. Earlier in his career, he held a number of commercial roles with increasing responsibility at Abbott Laboratories’ Pharmaceutical and Nutrition divisions.

Frye received a bachelor’s degree in psychobiology from the University of Southern California and master’s degree in marketing from the Anderson School of Management at the University of California.

What is Andrew Frye's net worth?: The estimated net worth of Andrew Frye is at least $301,788.58 as of April 12th, 2021. Mr. Frye owns 9,041 shares of Baxter International stock worth more than $301,789 as of November 22nd. This net worth evaluation does not reflect any other assets that Mr. Frye may own. Learn More about Andrew Frye's net worth.
How do I contact Andrew Frye?: The corporate mailing address for Mr. Frye and other Baxter International executives is One Baxter Parkway DF2-1W, Deerfield IL, 60015. Baxter International can also be reached via phone at (224) 948-2000 and via email at [email protected]. Learn More on Andrew Frye's contact information.
Has Andrew Frye been buying or selling shares of Baxter International?: Andrew Frye has not been actively trading shares of Baxter International over the course of the past ninety days. Most recently, Andrew Frye sold 10,999 shares of the business's stock in a transaction on Monday, April 12th. The shares were sold at an average price of $84.79, for a transaction totalling $932,605.21. Following the completion of the sale, the senior vice president now directly owns 9,041 shares of the company's stock, valued at $766,586.39. Learn More on Andrew Frye's trading history.
Who are Baxter International's active insiders?: Baxter International's insider roster includes Giuseppe Accogli (SVP), John Forsyth (Director), Andrew Frye (SVP), James Gavin, III (Director), Jacqueline Kunzler (SVP), Sean Martin (SVP), Jeanne Mason (SVP), Brian Stevens (CAO), and Albert Stroucken (Director). Learn More on Baxter International's active insiders.

Andrew Frye Insider Trading History at Baxter International

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/12/2021	Sell	10,999	$84.79	$932,605.21	9,041
6/3/2020	Sell	3,742	$91.00	$340,522.00	16,216
10/14/2019	Sell	3,332	$88.00	$293,216.00	16,391

Andrew Frye Buying and Selling Activity at Baxter International

Baxter International Company Overview

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Today's Range

Now: $33.21

$33.01

$33.70

50 Day Range

MA: $36.21

$31.71

$40.26

2 Week Range

Now: $33.21

$31.60

$44.01

Volume

4,640,657 shs

Average Volume

4,107,361 shs

Market Capitalization

$16.96 billion

P/E Ratio

166.06

Dividend Yield

3.57%

Beta

0.6

This company will win the AI race

From Porter & Company | Ad